Related Experiment Video
Updated: Jun 22, 2026

Cortical Bone Assessment Using Ultrasonic Guided Waves: A Reproducibility Study in a Healthy Population
Published on: January 31, 2025
SSRIs, bone mineral density, and risk of fractures--a review
1Uppsala County Council, Uppsala Drug Information Center, Sweden.
Abstract:
A possibility for selective serotonin reuptake inhibitors (SSRIs) to increase the risk of bone fracture has been debated during recent years. Proposed causes include an ability for the drugs to reduce bone mineral density (BMD). Experimental data have identified a functional 5-HT system in bone, although its role is unclear. Results from numerous epidemiological studies are heterogeneous and several different associations have been suggested; between depression and low BMD, SSRIs and low BMD, depression and falls, SSRIs and falls, depression and fractures, and SSRIs and fractures. In this paper, we review the available data and discuss the various study results. Based on the current available data, we conclude that it is not possible to determine whether SSRIs may negatively influence bone regulation or are innocent bystanders. It is likely that only a large, prospective, long-term study designed to investigate changes in BMD will be able to answer the question.
Insights
Selective serotonin reuptake inhibitors (SSRIs) may affect bone health, but evidence is inconclusive. Further long-term studies are needed to determine if SSRIs impact bone mineral density and fracture risk.
Area of Science:
- Pharmacology
- Bone Biology
- Epidemiology
Background:
- Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed antidepressants.
- A potential link between SSRI use and increased fracture risk has been proposed.
- SSRIs may influence bone mineral density (BMD), but the mechanism is unclear.
Purpose of the Study:
- To review and discuss the current evidence regarding SSRIs and bone health.
- To evaluate the association between SSRIs, BMD, and fracture risk.
- To identify gaps in current research and suggest future study designs.
Main Methods:
- Literature review of epidemiological and experimental studies.
- Analysis of heterogeneous study results on SSRIs, depression, BMD, falls, and fractures.
- Discussion of the functional 5-HT system in bone.
Main Results:
- Epidemiological studies show inconsistent associations between SSRIs, depression, BMD, falls, and fractures.
- Experimental data suggest a functional serotonin system in bone, but its role is not fully understood.
- Current data are insufficient to establish a causal link between SSRIs and negative bone health outcomes.
Conclusions:
- It is not possible to definitively conclude whether SSRIs negatively influence bone regulation.
- SSRIs might be innocent bystanders in the observed associations with bone health.
- Large, prospective, long-term studies focusing on BMD changes are required to resolve this question.
Related Concept Videos
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
Osteoclasts in Bone Remodeling
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Bone Remodeling
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...